---
title: "Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295132865.md"
description: "Viatris agreed to sell its dry eye drug Tyrvaya to Harrow for up to $100 million, aiming to focus on high-potential growth areas. Following a second-quarter earnings and revenue beat, Viatris raised its full-year 2026 adjusted earnings guidance to $2.45-$2.49 per share and sales guidance to $14.55-$14.95 billion."
datetime: "2026-08-06T17:56:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295132865.md)
  - [en](https://longbridge.com/en/news/295132865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295132865.md)
generator: "portal-rs"
---

# Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

**Harrow Inc.** (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from **Viatris Inc.** (NASDAQ:VTRS).

## Viatris To Sell Tyrvaya To Harrow In Up To $100 Million Deal

Tyrvaya is a cholinergic agonist indicated for signs and symptoms of dry eye disease and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries.

Harrow will pay $30 million in cash and up to $70 million in contingent milestone payments tied to Tyrvaya’s net sales, for a potential total consideration of up to $100 million.

The transaction is expected to close in the second half of 2026.

 **Read Also: RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding** 

## Viatris Q2 Performance

Viatris on Thursday reported second-quarter adjusted earnings of 69 cents per share, beating the consensus of 60 cents.

The generic drug maker reported sales of $3.756 billion, ahead of the consensus of $3.675 billion.

Sales jumped 5% year over year (+3.5% on an operational basis), primarily driven by new product sales in Developed Markets and strong growth in Greater China.

“Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we’re building across our business,” said **Scott A. Smith,** CEO, Viatris. “Commercial execution, pipeline progress and the early benefits of our enterprise-wide strategic review continue strengthening our business and improving our financial performance.”

In the company earnings conference call, Viatris said the Tyrvaya deal will help it focus on high-potential growth areas, particularly in complex generics and transdermal products, as well as continued investment in the Greater China market.

## Viatris Raises 2026 Earnings And Sales Guidance

“Our strong first-half results give us the confidence to raise our full-year guidance. We expect a more balanced operating environment in the second half of the year, and we remain focused on disciplined execution, investing behind our future growth drivers and creating long-term value for patients and shareholders,” Smith said.

Viatris raised its fiscal 2026 adjusted earnings guidance from $2.33-$2.47 per share to $2.45-$2.49 compared to the consensus of $2.44.

The company raised its 2026 sales guidance from $14.45 billion-$14.95 billion to $14.55 billion-$14.95 billion versus the Wall Street estimate of $14.783 billion.

**VTRS Price Action:** Viatris shares were down 4.16% at $16.91 at the time of publication on Thursday, according to Benzinga Pro data.

 **Read Also: SpaceX, Tesla Confirm Terafab Site as Chip Demand Outruns Global Supply** 

*Image via Shutterstock*

### Related Stocks

- [VTRS.US](https://longbridge.com/en/quote/VTRS.US.md)
- [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md)
- [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md)
- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)
- [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [Harrow management to attend Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297640870.md)
- [REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US](https://longbridge.com/en/news/297206158.md)
- [Altria announces Q3 2026 dividend of R$ 0.78 per unit, payable Oct. 16](https://longbridge.com/en/news/297826085.md)
- [Harrow to buy dry eye nasal spray Tyrvaya from Viatris for up to $100 million](https://longbridge.com/en/news/295096536.md)
- [Ocumension completes enrollment in China Phase III trial of dry eye drug OT-211](https://longbridge.com/en/news/297783885.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**